Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

BACKGROUND: Sorafenib and sunitinib are widely used as first-line targeted therapy for metastatic renal cell carcinoma (mRCC) in China. This study aimed to compare the efficacy, safety, and quality of life (QoL) in Chinese mRCC patients treated with sorafenib and sunitinib as first-line therapy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Wen, Kong, Wen, Dong, Baijun, Zhang, Jin, Chen, Yonghui, Xue, Wei, Huang, Yiran, Zhou, Lixin, Huang, Jiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547674/
https://www.ncbi.nlm.nih.gov/pubmed/28789709
http://dx.doi.org/10.1186/s40880-017-0230-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547674/
https://www.ncbi.nlm.nih.gov/pubmed/28789709
http://dx.doi.org/10.1186/s40880-017-0230-7

Ejemplares similares